Delivered strong FY2026 results with 9.4% revenue growth and expanding MedTech segment, driven by robust performance in Auryon, AlphaVac, and NanoKnife. FY2027 guidance projects continued MedTech growth, stable margins, and ongoing investment in clinical data and innovation.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.